All In Biotech

Free tool

FAERS Monitor: Evoxac

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 020989 or its brand name (Evoxac, Cevimeline Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

2,791

Serious

1,462

52% of reports

Hospitalization

676

Death reported

109

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective218
  • headache184
  • nausea171
  • diarrhoea169
  • fatigue162
  • dyspnoea146
  • pain133
  • arthralgia124
  • off label use111
  • fall109
  • malaise100
  • dizziness97
  • vomiting94
  • dry mouth92
  • pneumonia92

Reports by year received

View as table
YearReports
200430
200529
200631
200739
200841
200954
201068
201174
201297
2013123
2014105
2015174
2016251
2017164
2018177
2019196
2020151
2021125
2022152
2023133
2024196
2025181
2026200

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,368 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
dry mouthSignal928.67.0608
fallSignal1092.52.195
arthralgiaSignal1242.21.986
headacheSignal1842.21.9125
pneumoniaSignal922.11.856
diarrhoea1692.01.783
dyspnoea1461.91.768
malaise1001.71.430
pain1331.61.433
nausea1711.61.442
fatigue1621.61.434
vomiting941.51.216
dizziness971.51.214
drug ineffective2181.21.111
off label use1111.00.80

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.